These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Quantitative Antisense Screening and Optimization for Exon 51 Skipping in Duchenne Muscular Dystrophy. Echigoya Y; Lim KRQ; Trieu N; Bao B; Miskew Nichols B; Vila MC; Novak JS; Hara Y; Lee J; Touznik A; Mamchaoui K; Aoki Y; Takeda S; Nagaraju K; Mouly V; Maruyama R; Duddy W; Yokota T Mol Ther; 2017 Nov; 25(11):2561-2572. PubMed ID: 28865998 [TBL] [Abstract][Full Text] [Related]
10. [Mutation-specific treatments for Duchenne muscular dystrophy]. Matsuo M; Takeshima Y Brain Nerve; 2009 Aug; 61(8):915-22. PubMed ID: 19697880 [TBL] [Abstract][Full Text] [Related]
11. Contributions of Japanese patients to development of antisense therapy for DMD. Matsuo M; Takeshima Y; Nishio H Brain Dev; 2016 Jan; 38(1):4-9. PubMed ID: 26094594 [TBL] [Abstract][Full Text] [Related]
12. Exon skipping: a first in class strategy for Duchenne muscular dystrophy. Niks EH; Aartsma-Rus A Expert Opin Biol Ther; 2017 Feb; 17(2):225-236. PubMed ID: 27936976 [TBL] [Abstract][Full Text] [Related]
13. [Development of novel therapeutic approaches for Duchenne muscular dystrophy]. Takeshima Y No To Hattatsu; 2014 Mar; 46(2):109-14. PubMed ID: 24738186 [No Abstract] [Full Text] [Related]
14. New developments in the use of gene therapy to treat Duchenne muscular dystrophy. Jarmin S; Kymalainen H; Popplewell L; Dickson G Expert Opin Biol Ther; 2014 Feb; 14(2):209-30. PubMed ID: 24308293 [TBL] [Abstract][Full Text] [Related]